LIFE / aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with str more_horizontal

Atyr Pharma (LIFE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of more_horizontal

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of fi more_horizontal

Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of more_horizontal

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Re more_horizontal

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal

Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

aTyr Pharma, Inc. (NASDAQ:LIFE ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Ashlee Dunston - Director, IR & Co more_horizontal